peptide elongation factor 2 has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Du, M; Hou, J; Hu, L; Hui, Y; Li, G; Wei, X; Zhang, J; Zhang, X | 1 |
| Kasman, LM; Kelly, MM; Lu, P; McDermott, PJ; Spruill, L; Voelkel-Johnson, C; White, SJ | 1 |
2 other study(ies) available for peptide elongation factor 2 and Prostatic Neoplasms
| Article | Year |
|---|---|
Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Humans; Male; Middle Aged; Peptide Elongation Factor 2; Prostatic Neoplasms | 2018 |
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cell Line, Tumor; Deferoxamine; Doxorubicin; Drug Synergism; Free Radicals; Humans; Hydrogen Peroxide; Iron Chelating Agents; Male; Peptide Elongation Factor 2; Phenotype; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Protein Synthesis Inhibitors; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2007 |